# A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

> **NCT07341828** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Huashan Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Multiple Sclerosis (MS)
- Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Autoimmune Encephalitis
- Stiff Person Syndrome

## Interventions

- **BIOLOGICAL:** CD20/BCMA-directed CAR-T cells

## Key facts

- **NCT ID:** NCT07341828
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-06
- **Final completion:** 2029-02
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07341828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07341828, "A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07341828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*